Please use this identifier to cite or link to this item:
Title: The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial
Authors: Nazir, Sheraz A.
Khan, J. N.
Mahmoud, I. Z.
Greenwood, J. P.
Blackman, D. J.
Kunadian, V.
Been, M.
Abrams, K. R.
Wilcox, R.
Adgey, A. A.
McCann, G. P.
Gershlick, A. H.
First Published: 25-Sep-2014
Publisher: BioMed Central
Citation: Trials, 2014, 15, p. 371
Abstract: Microvascular obstruction (MVO) secondary to ischaemic-reperfusion injury is an important but underappreciated determinant of short- and longer-term outcome following percutaneous coronary intervention (PCI) treatment of ST-elevation myocardial infarction (STEMI). Several small studies have demonstrated a reduction in the degree of MVO utilising a variety of vasoactive agents, with adenosine and sodium nitroprusside (SNP) being most evaluated. However, the evidence base remains weak as the trials have had variable endpoints, differing drug doses and delivery. As such, the results regarding benefit are conflicting.
DOI Link: 10.1186/1745-6215-15-371
eISSN: 1745-6215
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Description: PMCID: PMC4189551
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
1745-6215-15-371.pdfPublished (publisher PDF)1.33 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.